Department of Oncology and Advanced Technologies, Operative Unit of Pathologic Anatomy, Azienda Arcispedale S. Maria Nuova/IRCCS, Reggio Emilia, Italy.
Adv Anat Pathol. 2013 Sep;20(5):327-33. doi: 10.1097/PAP.0b013e3182a28a24.
Non-small cell lung cancer is possibly the solid tumor with more potential drugable molecular targets, but the smallest tumor specimens. An optimization of tumor tissue handling is then mandatory. In this landscape, the precise definition of non-small cell lung cancer histologic type had a renewal role in selecting different therapeutic strategies, also leading to a large use of immunohistochemistry even in malignancies showing an overt morphologic differentiation. We suggest here 4 different clinicopathologic scenarios with some helpful rules aimed at preventing unnecessary and expensive immunostains, then underlining the ageless value of morphology and preserving tumor tissues for molecular investigations.
非小细胞肺癌可能是实体肿瘤中具有最多潜在可药物治疗分子靶点的肿瘤，但肿瘤标本通常较小。因此，必须优化肿瘤组织处理。在这种情况下，明确非小细胞肺癌组织学类型的定义在选择不同治疗策略方面发挥了新的作用，甚至在形态学分化明显的恶性肿瘤中也大量使用免疫组织化学。在这里，我们提出了 4 种不同的临床病理情况，并提出了一些有用的规则，旨在防止不必要和昂贵的免疫染色，同时强调形态学的永恒价值，并为分子研究保存肿瘤组织。
